FDA recommends against using Exparel as regional nerve block

1297 Views

eMediNexus 25 February 2018

The US Food and Drug Administrations (FDAs) Anesthetic and Analgesic Drug Products Advisory Committee has voted 6 to 4 against recommending bupivacaine liposomal injectable suspension (Exparel, Pacira Pharmaceuticals Inc) as a nerve block to treat regional postsurgical pain.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.